ProQR Therapeutics BV (PRQR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ProQR Therapeutics BV (PRQR) has a cash flow conversion efficiency ratio of -0.214x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.23 Million) by net assets ($57.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PRQR defensive interval ratio to measure how many days the company can operate on defensive assets alone.
ProQR Therapeutics BV - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how ProQR Therapeutics BV's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ProQR Therapeutics BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProQR Therapeutics BV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Thryv Holdings Inc
NASDAQ:THRY
|
0.101x |
|
Precision Camshafts Limited
NSE:PRECAM
|
0.079x |
|
Goodbaby International Holdings Limited
F:GBH
|
0.041x |
|
Cristales
SN:CRISTALES
|
-0.025x |
|
Kao Fong Machinery Co Ltd
TWO:4510
|
-0.001x |
|
Portman Ridge Finance Corp
NASDAQ:PTMN
|
-0.003x |
|
Ecomate Holdings Bhd
KLSE:0239
|
-0.103x |
|
Auna S.A.
NYSE:AUNA
|
0.052x |
Annual Cash Flow Conversion Efficiency for ProQR Therapeutics BV (2013–2024)
The table below shows the annual cash flow conversion efficiency of ProQR Therapeutics BV from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market value of ProQR Therapeutics BV.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $88.56 Million | $-36.39 Million | -0.411x | -187.20% |
| 2023-12-31 | $45.72 Million | $21.55 Million | 0.471x | +145.87% |
| 2022-12-31 | $66.68 Million | $-68.51 Million | -1.027x | -347.22% |
| 2021-12-31 | $113.23 Million | $-26.01 Million | -0.230x | +66.23% |
| 2020-12-31 | $69.19 Million | $-47.06 Million | -0.680x | -62.93% |
| 2019-12-31 | $105.33 Million | $-43.97 Million | -0.417x | -26.11% |
| 2018-12-31 | $92.69 Million | $-30.68 Million | -0.331x | +62.75% |
| 2017-12-31 | $39.33 Million | $-34.95 Million | -0.889x | -38.00% |
| 2016-12-31 | $53.14 Million | $-34.22 Million | -0.644x | -138.66% |
| 2015-12-31 | $89.80 Million | $-24.23 Million | -0.270x | -104.21% |
| 2014-12-31 | $109.40 Million | $-14.46 Million | -0.132x | -100.50% |
| 2013-12-31 | $-89.00K | $-2.33 Million | 26.202x | -- |
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-sta… Read more